Recent developments include the company’s financial turnaround and growth as reported in April 2026, highlighting expansion of CDMO activities and capital raising efforts.

• Scinai Immunotherapeutics reported financial turnaround and growth, with revenues increasing to $1.3 million in 2025 driven by expansion of CDMO activities and growing customer engagement [N1].
• The company completed the acquisition of Recipharm Israel Ltd. in February 2026, expanding its manufacturing footprint and capabilities [S1].
• In February 2026, Scinai received a non-dilutive grant of approximately $310,000 from the Israel Innovation Authority to fund advanced sterile manufacturing equipment [S1].
• The company continues to incur operating losses as it invests in CDMO scale-up and therapeutic development programs, with ongoing capital raising efforts to support operations [N1][S1].

Scinai has established a diversified biopharmaceutical platform combining innovative therapeutic development with contract manufacturing services. Its collaborations with leading research institutions and acquisition of manufacturing capabilities position it to serve a broad range of clients and advance its proprietary pipeline. The expansion of CDMO revenues and recent capital raises demonstrate operational progress and investor support. The company's NanoAbs technology and PC111 program offer potential for novel treatments in inflammation and immunology, which could create future value if clinical development advances.

The company faces substantial financial challenges, including ongoing operating losses, limited cash reserves, and substantial doubt about its ability to continue as a going concern without additional financing. Its therapeutic programs are in early stages with inherent clinical and regulatory risks, and the failure of prior candidates underscores development uncertainties. The CDMO business currently operates at a loss and requires further scale-up to reach breakeven. The company’s reliance on external funding and grants introduces execution risk, and competitive pressures in biopharmaceutical development and manufacturing may constrain growth.

Scinai's moat is based on its proprietary NanoAbs platform developed in collaboration with prestigious academic institutions, providing unique nanosized antibody therapeutics with potential advantages in binding affinity and administration routes. The company's integrated CDMO services, including recent expansion through acquisition, offer a comprehensive manufacturing and development platform for early-stage biotech clients, potentially creating customer stickiness. However, the company operates in a competitive biopharmaceutical landscape with significant capital requirements and clinical development risks, limiting the strength of its moat at this stage.

• Financing Risk: The company’s current cash position is insufficient to fund planned operations for at least one year, creating substantial doubt about its ability to continue as a going concern without additional financing. Failure to secure adequate funding could lead to delays, reductions, or cessation of operations.
• Clinical and Development Risk: Therapeutic development programs face inherent risks including clinical trial failures, regulatory hurdles, and uncertain timelines. The failure of the M-001 vaccine candidate highlights these risks.
• Operational Risk: The CDMO business currently operates at a loss and requires successful scale-up and customer acquisition to achieve profitability. Integration of acquired assets and expansion of capabilities present execution challenges.
• Market and Competitive Risk: The biopharmaceutical and CDMO markets are highly competitive with rapid technological changes. The company must maintain innovation and operational efficiency to remain competitive.

• Scinai Immunotherapeutics Ltd. is a biopharmaceutical company based in Israel with two main business units: (i) Scinai R&D focused on developing innovative therapeutics in inflammation and immunology, and (ii) a contract development and manufacturing organization (CDMO) business operating through its subsidiary Scinai Biopharma Services Ltd.
• The company acquired Recipharm Israel Ltd. in February 2026, expanding its CDMO capabilities to include small-molecule development alongside biologics manufacturing.
• Scinai's R&D pipeline includes the PC111 program, a fully human monoclonal antibody targeting keratinocyte cell death and inflammation, and a NanoAbs platform developing nanosized antibody therapeutics in collaboration with the Max Planck Society and University Medical Center Göttingen.
• The company has executed eight clinical trials historically, including a large phase 3 trial for a universal influenza vaccine candidate (M-001) which failed to meet endpoints, leading to a strategic turnaround and refocus on NanoAbs and other assets.
• CDMO services include analytical method development, process development, cGMP manufacturing, fill and finish operations, and quality control, supported by facilities in Jerusalem and Yavne, Israel, designed to meet EMA and FDA requirements.
• Financial snapshot as of December 31, 2025: revenues of $1.31 million, net loss of $8.3 million, cash and cash equivalents of $1.66 million, current assets of $2.05 million, current liabilities of $1.59 million, current ratio of 1.3, and cash ratio of 1.05.
• Revenues increased from $0.7 million in 2024 to $1.3 million in 2025, reflecting expansion of CDMO activities and growing customer engagement.
• Research and development expenses decreased from $5.6 million in 2024 to $2.4 million in 2025, primarily due to reduced allocation of employees and facilities to R&D.
• Marketing, general and administrative expenses remained stable at $2.6 million for both 2024 and 2025.
• Financial income net decreased from $13.5 million in 2024 (mainly from loan conversion income) to $1 million in 2025, primarily from exchange rate differences and fees.
• The company has a history of funding operations through equity offerings, grants from the Israel Innovation Authority (IIA), European grants, and loans from the European Investment Bank (EIB).
• The EIB loan was restructured in 2024, converting approximately $29 million of debt into preferred shares, leaving a small outstanding amount with no interest and maturity in 2031.
• The company’s cash position as of December 31, 2025, is not sufficient to fund planned operations for at least one year, creating substantial doubt about its ability to continue as a going concern without additional financing.
• The company has entered into a Standby Equity Purchase Agreement with YA II PN, Ltd. to raise up to $10 million, with drawdowns of $1.5 million and $4.2 million in 2025.
• In February 2026, Scinai was awarded a non-dilutive grant of approximately $310,000 from the Israel Innovation Authority to fund a project for advanced fill-and-finish sterile manufacturing equipment.
• The company continues to incur operating losses as its CDMO business operates at a loss and its R&D programs require ongoing investment without product revenue support.
• The company’s management acknowledges the need for substantial additional financing to continue operations, support CDMO growth, and advance therapeutic development programs.
• The company’s financial statements are prepared on a going concern basis but include a note on substantial doubt due to current cash constraints and financing needs.
• The company’s board and management include experienced executives with backgrounds in biopharmaceutical development and healthcare strategy.
• The company has policies and procedures to manage cybersecurity risks, including third-party vendor oversight, with no material cybersecurity incidents reported to date.
• Research and development grants from the IIA and European Union are recorded as reductions to R&D expenses, with no expected repayment liabilities due to discontinued programs.
• The company’s CDMO business supports early-stage biotech clients from development through clinical-stage production, emphasizing flexibility and regulatory compliance.